This study aimed to compare lysyl oxidase-1 level in diabetic patients with and without renal dysfunction, that LOX-1 may be an indicator for the early stage of diabetic nephropathy (DN). In addition to finding it is a relationship with kidney functions in Iraqi diabetic patients with and without renal dysfunction. Blood was obtained from 25 healthy individuals as a control group (G1), 25 diabetic patients with renal dysfunction, and 25 diabetic patients without renal dysfunction. Age range 40-60 years for all subjects. BMI (25-27) Kg/m2 . The serum was used for the analysis of LOX-1, FBG, urea, creatinine and uric acid. Whole blood is used for the determination of HbA1C. Results of FBG and HbA1C revealed a significant increase in G2 and G3 compared to G1. While a non-significant rise was found between G2 and G3. Results, also, showed non-significant differences between G1, G2and G3. Urea, creatinine, and uric acid levels showed a significant elevation in G2 comparing to G1 and G3.In addition to a non-significant increase in G1 compared to G3. Results for LOX-1 illustrated a significant rise in G2 and G3 compared to G1. Also, a significant elevation was found in G2 comparing to G3. Results, also, showed a significant correlation for LOX-1 with FBG, HbA1C%, Urea, Creatinine and Uric acid in G1, G2 and G3. In conclusion, this study was proved a relationship between LOX-1 and the first stage of DN and this suggests that the LOX-1 possibly will be considered as a biomarker for detection of early-stage of DN, which leads to design treatment plans, as a novel possible healing aims.